A patient with mildly symptomatic, Stage III, Grade 2, FLIPI high-risk follicular lymphoma in partial remission after rituximab/chemotherapyA patient with mildly symptomatic, Stage III, Grade 2, FLIPI high-risk follicular lymphoma in partial remission after rituximab/chemotherapy
Editor's comments
Dr Williams points out that 2 years of rituximab maintenance has become standard after induction rituximab/chemotherapy, and these results confirm that. However, he also notes that a survival benefit has not yet been documented, and therefore he does not hesitate to stop treatment in patients having difficulty tolerating rituximab maintenance. survey data
 select references with links
Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients. World J Clin Oncol 2011;2(7):281-8. Abstract Nabhan C et al. Maintenance rituximab in follicular non-Hodgkin lymphoma: Facts and controversies. Leuk Lymphoma 2012;53(5):770-8. Abstract Salles GA et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51. Abstract |